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Bevacizumab therapy before
autologous stem-cell
transplantation for POEMS
syndrome
POEMS is an acronym for a rare multisystemic syndrome
encompassing polyneuropathy (P), organomegaly (O),
endocrinopathy (E), monoclonal gammopathy (M), skin
changes (S) and additional features variably expressed [1].
POEMS syndrome is associated with high vascular endothelial
growth factor (VEGF) serum levels. This angiogenic factor
likely plays a pathogenic role, in particular for neuropathy,
possibly via alteration of endoneurial vessels [2]. Treatment
options are still debated, but recently autologous stem-cell
transplantation (ASCT) appears to be effective. This approach
for POEMS patients, however, was associated with severe
morbidity, mainly respiratory failures that appeared to be
related to neuromuscular damage [3].
We report a 45-year-old woman presenting with a rapidly
progressive sensorimotor polyneuropathy involving all
extremities, multiple sclerotic bone lesions, skin
hyperpigmentation and hemangiomas, hepatomegaly,
peripheral edema and papilledema. A monoclonal
immunoglobulin A k protein was detected (5 g/l) with a bone
marrow plasmocytosis (15%). Platelets were 600 · 109/l and
cerebrospinal fluid proteins were 30 g/l. Electromyographic and
nerve conduction analyses confirmed neuropathy with axonal
abnormalities. Within few months appeared walking
impossibility, swallowing difficulties and respiratory distress.
Serum VEGF was highly elevated at 9700 pg/ml (normal
range: 62–707).
Steroids treatment was declined by the patient. ASCT was
considered at high risk because of her poor condition
(Karnofsky score of 50%), neurological defects and respiratory
failure. We hypothesized that VEGF inhibition may relieve
neuropathy. Bevacizumab therapy was initiated at 10 mg/kg
every 2 weeks. Pain relief was observed after two infusions,
followed by major improvement in walking and breathing
within 10 weeks. This was correlated with a drop in VEGF level
(61 pg/ml) and a significant improvement in
electromyographic and nerve conduction studies. Treatment
was continued for 4 months, and further clinical improvement
was observed, confirmed by electroneuromyography and
pulmonary function tests. Hepatomegaly and skin
abnormalities remained unchanged. Karnofsky score
improved at 80%, allowing ASCT conditioned with melphalan
(200 mg/m2) to be realized in better conditions. The procedure
was well tolerated, and clinical outcome was excellent with
a Karnofsky score at 90% 1 year after the procedure.
Rapidly evolving neuropathy may hamper to carry out
ASCT in POEMS patients. Neurological defects in our POEMS
patient has been partially reversed by bevacizumab therapy,
further supporting the role of VEGF in this complication.
The large biological and clinical heterogeneities of POEMS
syndrome could explain variable sensitivities to anti-VEGF
therapy [4, 5]. Our report indicates that some patients may
benefit from bevacizumab to improve their clinical condition
before applying more standard treatments.
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